Sanofi sets sights on Africa with an eye on M&A

A few days after a similar announcement from GlaxoSmithKline ($GSK), Sanofi ($SNY) said it plans to scale up its presence in Africa, looking to invest in marketing and R&D in response to the market's continued growth. CEO Chris Viehbacher said the company has opened plants on the continent to produce drugs for malaria and HIV, and Sanofi is moving forward with development programs for neurological disorders including epilepsy and depression. For its part, GSK has said that it will spend more than $200 million over the next 5 years on R&D projects in the region. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.